Your browser is no longer supported. Please, upgrade your browser.
Instil Bio, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own6.91% Shs Outstand128.74M Perf Week-1.10%
Market Cap2.35B Forward P/E- EPS next Y-1.59 Insider Trans0.00% Shs Float119.86M Perf Month-14.11%
Income-71.70M PEG- EPS next Q-0.32 Inst Own55.00% Short Float4.05% Perf Quarter-7.11%
Sales0.05M P/S46028.73 EPS this Y-478.60% Inst Trans0.01% Short Ratio23.12 Perf Half Y7.26%
Book/sh4.94 P/B3.65 EPS next Y-22.30% ROA- Target Price30.00 Perf Year-
Cash/sh4.35 P/C4.14 EPS next 5Y- ROE- 52W Range14.42 - 29.49 Perf YTD-31.85%
Dividend- P/FCF- EPS past 5Y- ROI85.30% 52W High-37.86% Beta-
Dividend %- Quick Ratio24.10 Sales past 5Y- Gross Margin- 52W Low27.08% ATR1.36
Employees150 Current Ratio24.10 Sales Q/Q- Oper. Margin- RSI (14)47.34 Volatility4.62% 7.10%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.42 Prev Close18.02
ShortableYes LT Debt/Eq0.00 EarningsAug 12 BMO Payout- Avg Volume210.14K Price18.33
Recom1.80 SMA20-4.18% SMA50-2.41% SMA200-3.45% Volume20,701 Change1.69%
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Sep-16-21 07:00AM  
Sep-15-21 04:27PM  
Sep-13-21 07:00AM  
Sep-02-21 07:00AM  
Aug-12-21 07:00AM  
Jul-19-21 02:34PM  
Jun-21-21 10:06AM  
Jun-01-21 07:00AM  
May-13-21 07:00AM  
Apr-29-21 08:45AM  
Apr-27-21 07:00AM  
Apr-12-21 07:18AM  
Mar-23-21 05:00PM  
Mar-19-21 04:25PM  
Mar-18-21 08:26PM  
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McGaughy R Kent JrDirectorMar 23Buy20.00450,0009,000,0008,478,790Mar 25 05:28 PM
Vivo Capital IX, LLC10% OwnerMar 23Buy20.00300,0006,000,00012,486,787Mar 25 05:32 PM
Crouch BronsonCEO and ChairmanMar 23Buy20.00450,0009,000,00037,980,073Mar 25 04:27 PM